Render Target: STATIC
Render Timestamp: 2024-12-26T11:50:45.372Z
Commit: f2d32940205a64f990b886d724ccee2c9935daff
XML generation date: 2024-08-01 15:28:25.679
Product last modified at: 2024-12-12T22:30:10.155Z
Cell Signaling Technology Logo
1% for the planet logo
PDP - Template Name: Polyclonal Antibody
PDP - Template ID: *******59c6464

MTA2 Antibody #15793

Filter:
  • WB

    Supporting Data

    REACTIVITY H M R Mk
    SENSITIVITY Endogenous
    MW (kDa) 75
    SOURCE Rabbit
    Application Key:
    • WB-Western Blotting 
    Species Cross-Reactivity Key:
    • H-Human 
    • M-Mouse 
    • R-Rat 
    • Mk-Monkey 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    MTA2 Antibody recognizes endogenous levels of total MTA2 protein. This antibody does not cross-react with other MTA proteins. This antibody detects a 50 kDa band of unknown origin in rat cell lysates.

    Species Reactivity:

    Human, Mouse, Rat, Monkey

    Source / Purification

    Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro602 of human MTA2 protein. Antibodies are purified by peptide affinity chromatography.

    Background

    MTA2 is a component of the NuRD deacetylase complex, which is recruited by MBD3 and modulates the enzymatic activity of the histone deacetylase core (1,2). MTA2 is highly related to MTA1, but both proteins exist in biologically distinct complexes, with MTA2 being associated with complexes containing Sin3a and CHD4 (3) MTA2 has been shown to bind ERα and repress its activity and contributes to estradiol- and tamoxifen-resistant breast cancers (4). Indeed, the MTA proteins are critical regulators of many biological functions in both cancer and non-cancer settings (5,6). MTA2 upregulation has been reported in a multitude of cancers, including hepatocellular carcinomas, colorectal cancers, gastric cancers, and esophageal cancers (7-10). MTA2 has also been described in B cell development, where it interacts with Aiolos and Ikaros to control target genes (11).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.